Jiyang Yu, Ph.D.
Affiliations: | Biomedical Informatics | Columbia University, New York, NY |
Area:
gene regulatory modelsGoogle:
"Jiyang Yu"Mean distance: 15.6
Parents
Sign in to add mentor| Andrea Califano | grad student | 2012 | Columbia | |
| (Integrating Functional Genomics with Systems Biology to Discover Drivers and Therapeutic Targets of Human Malignancies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zeleke TZ, Pan Q, Chiuzan C, et al. (2022) Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer |
| Roussel MF, Jonchere B, Williams J, et al. (2022) Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. Molecular Cancer Therapeutics |
| Zhao X, Wang P, Diedrich JD, et al. (2022) Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nature Communications. 13: 5401 |
| Chaudhary KR, Kinslow CJ, Cheng H, et al. (2022) Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports. 12: 10140 |
| Autry RJ, Paugh SW, Carter R, et al. (2020) Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer. 1: 329-344 |
| Tosello V, Bongiovanni D, Liu J, et al. (2020) Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia |
| Hao Shi, Yan KK, Ding L, et al. (2020) Network Approaches for Dissecting the Immune System. Iscience. 23: 101354 |
| Marks DK, Gartrell RD, El Asmar M, et al. (2020) Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology. 10: 968 |
| Wijaya J, Vo BT, Liu J, et al. (2020) An ABC transporter drives medulloblastoma pathogenesis by regulating Sonic Hedgehog signaling. Cancer Research |
| Silva J, Kalinsky K, Chiuzan C, et al. (2020) Abstract CT107: Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC) Cancer Research. 80 |